Potassium

Potassium

SCHEMBL16909490

Cc1nc2ccc(-c3cnc(CC4CCC(C(=O)O)CC4)nc3)cn2c1Cc1ccccc1OC(F)F.[K]

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALKBH1 Q13686 1/20 0.37
SLC2A1 P11166 4/20 0.35
SYK P43405 2/20 0.34
PPARD Q03181 2/20 0.33
PPARA Q07869 1/20 0.33
TNF P01375 1/20 0.32
EPHB3 P54753 2/20 0.32
RIPK1 Q13546 1/20 0.32
CSNK1D P48730 1/20 0.32
CSNK1E P49674 1/20 0.32
MAP3K7 O43318 1/20 0.32
TAB1 Q15750 1/20 0.32
VCP P55072 2/20 0.31
SLC2A2 P11168 1/20 0.31
PDE4D Q08499 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16909486 0.98 ALKBH1 (0.37) ALKBH1SLC2A1SYKPPARDPPARA
Potassium Ion SCHEMBL16909487 0.92 ALKBH1 (0.35) ALKBH1SLC2A1PPARDPPARATNF
SCHEMBL16909391 0.91 ALKBH1 (0.34) ALKBH1SLC2A1SYKTNFSLC2A2
SCHEMBL16909815 0.89 ALKBH1 (0.38) ALKBH1SLC2A1PPARDPPARATNF
SCHEMBL16909556 0.89 ALKBH1 (0.38) ALKBH1SLC2A1PPARDPPARATNF
SCHEMBL16909558 0.89 ALKBH1 (0.38) ALKBH1SLC2A1PPARDPPARATNF
SCHEMBL16909695 0.86 ALKBH1 (0.38) ALKBH1SLC2A1PPARDPPARATNF
SCHEMBL16909640 0.86 ALKBH1 (0.41) ALKBH1SLC2A1TNF
SCHEMBL16909697 0.86 ALKBH1 (0.38) ALKBH1SLC2A1PPARDPPARATNF
Ammonia Solution, Strong SCHEMBL16909655 0.85 ALKBH1 (0.39) ALKBH1SLC2A1PPARDPPARATNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309243-B2 Imidazopyridine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2016-04-12 US claimed
EP-2872508-B1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2018-08-29 EP disclosed
US-9309243-B2 Imidazopyridine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2016-04-12 US disclosed
US-20150203486-A1 Imidazopyridine Derivatives as Modulators of TNF Activity UCB Biopharma SPRL a corporation 2015-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203486-A1 Imidazopyridine Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, IL1A ALKBH1 4341/4885SLC2A1 3939/4885SYK 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.